ATE154244T1 - Induzierung eines schutzes gegen virale infektionen - Google Patents

Induzierung eines schutzes gegen virale infektionen

Info

Publication number
ATE154244T1
ATE154244T1 AT91906386T AT91906386T ATE154244T1 AT E154244 T1 ATE154244 T1 AT E154244T1 AT 91906386 T AT91906386 T AT 91906386T AT 91906386 T AT91906386 T AT 91906386T AT E154244 T1 ATE154244 T1 AT E154244T1
Authority
AT
Austria
Prior art keywords
virus
protection against
viral infections
antibodies
against viral
Prior art date
Application number
AT91906386T
Other languages
English (en)
Inventor
Marc Girard
Marie-Paule Kieny
Claude Leclerc
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE154244T1 publication Critical patent/ATE154244T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT91906386T 1990-03-19 1991-03-16 Induzierung eines schutzes gegen virale infektionen ATE154244T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49474990A 1990-03-19 1990-03-19

Publications (1)

Publication Number Publication Date
ATE154244T1 true ATE154244T1 (de) 1997-06-15

Family

ID=23965805

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91906386T ATE154244T1 (de) 1990-03-19 1991-03-16 Induzierung eines schutzes gegen virale infektionen

Country Status (10)

Country Link
EP (2) EP0472706B1 (de)
JP (2) JPH03271233A (de)
AT (1) ATE154244T1 (de)
AU (3) AU651816B2 (de)
CA (1) CA2057040A1 (de)
DE (1) DE69126486T2 (de)
DK (1) DK0472706T3 (de)
ES (1) ES2104695T3 (de)
GR (1) GR3024670T3 (de)
WO (1) WO1991014449A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976541A (en) * 1988-01-26 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope
US5876724A (en) * 1990-03-19 1999-03-02 Institut Pasteur Induction of neutralizing antibody against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein
EP0536352B1 (de) * 1991-04-02 2003-12-17 Albert Einstein College Of Medicine Of Yeshiva University Therapeutischer- und präventivimpfstoff gegen hiv
US6139843A (en) * 1991-04-02 2000-10-31 Albert Einstein College Of Medicine Of Yeshiva University Peptide compositions for the treatment of HIV
CA2122263A1 (en) * 1991-10-28 1993-05-13 Marc Girard Induction of protection against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein
FR2692898B1 (fr) * 1992-06-30 1995-06-02 Centre Nat Rech Scient Procédé d'obtention de protéines membranaires, et utilisation de ces protéines dans un but de diagnostic ou de vaccination.
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
MX2021009020A (es) * 2019-01-28 2021-09-28 Xyphos Biosciences Inc Ligandos nkg2d no naturales modificados que entregan selectivamente moleculas heterologas unidas a receptores nkg2d no naturales en celulas car.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE87103T1 (de) * 1985-12-17 1993-04-15 Akzo Nv Immunochemisches reagenz.
NZ221440A (en) * 1986-08-20 1991-11-26 Genetic Systems Corp Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections
ES2080047T3 (es) * 1987-11-24 1996-02-01 Abbott Lab Peptidos hiv y metodos para la deteccion de hiv.
US5039522A (en) * 1988-01-29 1991-08-13 New York Blood Center, Inc. Immunogens containing peptides with an attached hydrophobic tail for adsorption to hepatitis B virus surface antigen
CA1341285C (en) * 1988-02-12 2001-08-14 Chang Yi Wang Synthetic peptides for the detection of antibodies to hiv gp120 envelope protein for diagnosis of aids and pre-aids conditions and as vaccines
FR2650954B1 (fr) * 1989-08-18 1992-02-28 Pasteur Institut Composition resultant de la reunion d'un epitope b de la glycoproteine d'enveloppe d'un retrovirus du type iv et d'un epitope t issu d'une proteine distincte codee par ce retrovirus et leur application a la production d'anticorps protecteurs contre le sida

Also Published As

Publication number Publication date
AU651816B2 (en) 1994-08-04
JPH04506220A (ja) 1992-10-29
EP0742229A3 (de) 1998-06-03
EP0742229A2 (de) 1996-11-13
AU7196098A (en) 1998-08-13
EP0472706A1 (de) 1992-03-04
WO1991014449A1 (en) 1991-10-03
CA2057040A1 (en) 1991-09-20
JPH03271233A (ja) 1991-12-03
AU6461594A (en) 1994-09-08
DE69126486T2 (de) 1998-01-15
DE69126486D1 (de) 1997-07-17
GR3024670T3 (en) 1997-12-31
ES2104695T3 (es) 1997-10-16
EP0472706B1 (de) 1997-06-11
DK0472706T3 (da) 1997-12-29
AU7498991A (en) 1991-10-21

Similar Documents

Publication Publication Date Title
EP0090581A3 (de) Kleine, für Maul- und Klauenseuche spezifische Peptide
ATE430200T1 (de) Impstoff gegen den für atemwegs- und reproduktionserkrankungen beim schwein verantwortlichen virus
NO20003526L (no) Proteiner kodet av polynukleinsyrer fra svinereproduktive- og respiratoriske syndromvirus (PRRSV)
ES2156199T3 (es) Polipeptido inductor de la produccion de interferon-gamma, anticuerpos monoclonales y composicion para el tratamiento o la prevencion de enfermedades sensibles al interferon-gamma.
WO2006041866A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
RU95122391A (ru) Адъюванты для вакцины против распираторно-синцитиального вируса
DE69111801D1 (de) Vakzin gegen hepatitis b.
CA2091263A1 (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
DE69322872D1 (de) Vakzine gegen immunodefizienz-virus der katze (kiv)
ATE154244T1 (de) Induzierung eines schutzes gegen virale infektionen
KR910000179A (ko) Aids용 결합체 면역원
WO2002057314A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational epitopes
ATE185073T1 (de) Impfstoff zubereitungen
KR920004422A (ko) Hiv의 주요 중화 결정인자
WO2004005316A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
ATE105190T1 (de) Ein b-epitop des huellglykoproteins eines retrovirus und ein t-epitop eines anderen proteins dieses retrovirus enthaltende zusammensetzung.
TR200202169T1 (tr) Tanı ve tedavide kullanım için pürifiye hepatit C virüsü zarf proteinleri.
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
KR950701821A (ko) 피임 백신(contraceptive vaccine)
SE9600436D0 (sv) Vaccine against hantavirus
CA2079230A1 (en) Bcrf1 antagonists for treating epstein-barr virus infections
RU93004854A (ru) Пептиды для вакцинации и индукции нейтрализующих антител против вируса иммунодефицита человека
KR970074790A (ko) 합성 펩티드를 함유하는 녹농균 백신 및 이것으로부터 생산된 치료제
DK0470989T3 (da) Anvendelse af monoklonale anti-beta2 mikroglobulin antistoffer
CA2143187A1 (en) Anti-feline immunodeficiency virus (fiv) vaccines

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee